CDK-IN-6

• CAT Number: I045035
• CAS Number: 779353-02-5
• Molecular Formula: C21H28N6O
• Molecular Weight: 380.49
• Purity: ≥95%
• Synonyms: 2-[(2S)-1-[3-ethyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
• InChI: InChI=1S/C21H28N6O/c1-2-17-15-24-27-19(23-14-16-6-5-9-22-13-16)12-20(25-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12-13,15,18,23,28H,2-4,7-8,10-11,14H2,1H3/t18-/m0/s1
• InChIKey: FWKFUJKFJMIJDX-SFHVURJKSA-N
• SMILES: CCC1=C2N=C(C=C(N2N=C1)NCC3=CN=CC=C3)N4CCCC[C@H]4CCO

CDK-IN-6（Cat No.:I045035）is a potent small-molecule inhibitor targeting cyclin-dependent kinases (CDKs), key regulators of cell cycle progression and transcription. By selectively inhibiting specific CDKs—such as CDK1, CDK2, or CDK9—CDK-IN-6 disrupts uncontrolled cell proliferation, making it a valuable compound in cancer research. It induces cell cycle arrest and may trigger apoptosis in rapidly dividing tumor cells. CDK-IN-6 is widely used in preclinical studies to explore CDK-driven oncogenic pathways and evaluate potential therapeutic strategies. Its selectivity and potency make it an important tool for studying cell cycle regulation and targeted anticancer therapies.